Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin vs MCT in Pediatric LC-FAOD
NCT05933200Phase 3Active, not recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Feb 2023
- Primary completion
- Aug 2027
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of triheptanoin in long-chain fatty acid oxidation disorder (LC-FAOD), sponsored by Ultragenyx Pharmaceutical Inc.. Started Feb 2023; status: active, not recruiting.
02
Drugs
triheptanoin
03
Conditions
long-chain fatty acid oxidation disorder (LC-FAOD)
Beyond the preview
Go deeper on NCT05933200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933200.